Evidence map›Paper›PMID 31728756›Full record

ArticleEndocrine2020

Liver-derived FGF21 is essential for full adaptation to ketogenic diet but does not regulate glucose homeostasis.

Mikiko Watanabe, Garima Singhal, Ffolliott M Fisher, Thomas C Beck, Donald A Morgan, Fabio Socciarelli, Marie L Mather, Renata Risi, Jared Bourke, Kamal Rahmouni and 3 more

Open access · greenAbstract read
In one paragraph

Article in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Fenofibrate Protects Against Antipsychotic-Induced Hyperglycemia Through Weight Loss and FGF21 Dependent Mechanisms.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Mikiko WatanabeDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Garima SinghalDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Ffolliott M FisherDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Thomas C BeckDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.
Donald A MorganDepartment of Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA.
Fabio SocciarelliDepartment of Oncology-Pathology, Karolinska Institutet, 171 76, Stockholm, Sweden.
Marie L MatherDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Renata RisiDepartment of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161, Rome, Italy.
Jared BourkeDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Kamal RahmouniDepartment of Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA.
Owen P McGuinnessDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.
Jeffrey S FlierDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
Eleftheria Maratos-FlierDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. emaratos@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USHarvard University · USUniversity of Iowa · USVanderbilt University · USKarolinska Institutet · SESapienza University of Rome · IT

Funding

STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4M
Transgenic CoreP30DK057521 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KAHN, BARBARA B. · 2000 to 2019
$31.4M
Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Amy Leanne Ryan · 1998 to 2026
$30.5M
Role of the brain Renin-Angiotensin Sys. in Cardiovas and Metabolic RegulationP01HL084207 · NHLBI · UNIVERSITY OF IOWA · PI GROBE, JUSTIN L · 2007 to 2022
$30.2M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI POWERS, ALVIN C · 1986 to 2011
$28.1M
Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI CORKEY, BARBARA E. · 1992 to 2021
$25.0M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
NUTRITION, INFECTION AND HEPATIC CARBOHYDRATE METABOLISMR01DK043748 · NIDDK · VANDERBILT UNIVERSITY · PI MCGUINNESS, OWEN P · 1997 to 2018
$7.9M
LEPTIN-- SIGNALING, TARGETS AND RESISTANCER37DK028082 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FLIER, JEFFREY S · 1992 to 2009
$5.7M
Metabolic Actions of FGF21R01DK028082 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FLIER, JEFFREY S · 1987 to 2018
$5.0M
American Heart Association 14EIA18860041NHLBI NIH HHS P01 HL084207NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK034854NIDDK NIH HHS P30 DK046200NIDDK NIH HHS P30 DK054759NIDDK NIH HHS P30 DK057521NIDDK NIH HHS P30 DK058404NIDDK NIH HHS P60 DK020593NIDDK NIH HHS R01 DK028082NIDDK NIH HHS R01 DK043748NIDDK NIH HHS R01 DK078188NIDDK NIH HHS R37 DK028082NIDDK NIH HHS U24 DK059637NIH HHS DK028082
6 · The paper itself

Abstract

backgroundFibroblast growth factor 21 (FGF21) is expressed in several metabolically active tissues, including liver, fat, and acinar pancreas, and has pleiotropic effects on metabolic homeostasis. The dominant source of FGF21 in the circulation is the liver. OBJECTIVE AND

methodsTo analyze the physiological functions of hepatic FGF21, we generated a hepatocyte-specific knockout model (LKO) by mating albumin-Cre mice with FGF21 flox/flox (fl/fl) mice and challenged it with different nutritional models.

resultsMice fed a ketogenic diet typically show increased energy expenditure; this effect was attenuated in LKO mice. LKO on KD also developed hepatic pathology and altered hepatic lipid homeostasis. When evaluated using hyperinsulinemic-euglycemic clamps, glucose infusion rates, hepatic glucose production, and glucose uptake were similar between fl/fl and LKO DIO mice.

conclusionsWe conclude that liver-derived FGF21 is important for complete adaptation to ketosis but has a more limited role in the regulation of glycemic homeostasis.

Indexed as

Diet, KetogenicFibroblast Growth FactorsAnimalsGlucoseHomeostasisLiverMiceMice, Knockoutfibroblast growth factor 21Fibroblast Growth FactorsGlucoseAdipose tissueCholesterolEnergy metabolismFibroblast Growth Factor 21Ketogenic dietNonalcoholic fatty liver disease

Identifiers

PMID31728756
PMCPMC7948212
OpenAlexW2987699973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.